John Pagel

The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Purpose of the Study: ME-401, a potent and selective oral PI3k inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938). 101 pts were...

Jamie Wood ;

Adam Asch ;

Igor Gorbatchevsky ;

John Pagel ;

Andrew Zelenetz ;

Nishitha Reddy ;

Deepa Jagadeesh ;

Anastasios Stathis ;

Huda Salman ;

Jacob Soumerai ;

Vaishalee Kenkre ;

Haresh Jhangiani ;

Judith Llorin-Sangalang ;

10/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 6 ⁠–⁠ November 8

November 7 ⁠–⁠ November 10

November 8 ⁠–⁠ November 10

November 8

November 13 ⁠–⁠ November 16

November 14 ⁠–⁠ November 15

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

See Full Calendar

John Pagel

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products